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ABSTRACT
Objectives: Overactive bladder syndrome (OAB) is a urinary condition
that often exerts detrimental effects on an individual’s quality of life
(QoL). A once-daily, extended-release (ER) formulation of the quaternary
amine trospium chloride has recently been developed for the treatment of
OAB. The pooled health-related QoL (HRQoL) data from two multi-
center, parallel-group, double-blind Phase III studies with trospium chlo-
ride ER 60 mg were analyzed.
Methods: Subjects aged 18 years with urinary urgency, frequency, and
an average of 1 urge urinary incontinence episode per day on a 3-day
bladder diary were randomized (1:1) to receive once-daily trospium
60 mg ER or placebo for 12 weeks. HRQoL was assessed at baseline and
at Week 12 using the King’s Health Questionnaire (KHQ) and the OAB
questionnaire (OAB-q).
Results: Overall, 1165 subjects were randomized (trospium ER, n = 578;
placebo, n = 587). Trospium ER produced signiﬁcantly greater improve-
ments from baseline than placebo in seven of the nine KHQ domains. At
Week 12, the improvement in mean OAB-q HRQoL total score (from
approximately 52 at baseline) was signiﬁcantly greater with trospium ER
than with placebo (+25.8 vs. +20.7; P = 0.0003). Improvements from
baseline were seen with trospium ER on all eight of the OAB-q symptom
bother scales.
Conclusions: Once-daily trospium 60 mg ER improved the QoL of sub-
jects with OAB, as assessed using the KHQ and the OAB-q, in two large
Phase III clinical trials.
Keywords: overactive bladder, quality of life, trospium chloride, urinary
incontinence.
Introduction
Overactive bladder syndrome (OAB) is a symptom complex com-
posed of urinary urgency, with or without urge urinary inconti-
nence (UUI), usually with increased daytime urinary frequency
and nocturia [1]. In the United States alone, 34 million adults are
affected, with the prevalence increasing with patient age [2]. The
symptoms of OAB may compromise a patient’s quality of life
(QoL), affecting social, physical, psychological, occupational,
and sexual aspects [3–5]. The effect on QoL can result in indi-
viduals developing complex coping strategies, including “toilet
mapping,” limiting travel, and avoiding social and sexual activi-
ties [6,7]. Urinary incontinence has also been associated with
loneliness [8], social isolation [9], and nursing home placement
of elderly patients [10–12].
Malone-Lee and colleagues have suggested that diagnosis of
OAB can be based on symptoms, allowing the majority of
patients to be treated within the primary care setting without the
need for specialist referral [13–16]. Naturalistic empirical treat-
ment of OAB by primary care physicians can improve OAB
symptoms as assessed using patient-reported outcomes (PROs)
and bladder diaries [17].
Antimuscarinic agent therapy results in improvements in the
core symptoms of OAB: urgency, frequency, UUI, and in some
cases, nocturia [18]. The inclusion of PROs in some trials
suggests that clinical beneﬁts are paralleled by improvements in
QoL [19,20]. Interestingly, in some instances, although objective
measures (frequency and bladder capacity) showed improve-
ments, subjects did not perceive a signiﬁcant beneﬁt in health-
related QoL (HRQoL) [19]. Despite the beneﬁts provided by the
currently available antimuscarinic agents, in a recent survey of
women with OAB, subjects expressed dissatisfaction with OAB
therapies, and the desire for more effective, convenient therapies
with fewer adverse events [3]. In another survey of patients with
urinary incontinence, among those who reported discontinuing
drug therapy, the major reasons were poor efﬁcacy, side effects,
and cost [21].
Trospium chloride is a quaternary amine antimuscarinic
agent that has been available in Europe for more than two
decades for the management of OAB. Results from two Phase III
clinical trials with the extended-release (ER) formulation indicate
that the efﬁcacy of once-daily trospium ER 60 mg is similar to
that seen previously with trospium immediate-release (IR) 20 mg
twice daily, while typical anticholinergic adverse events occurred
at lower rates (dry mouth rates with trospium ER 60 mg were
8.7%, 12.9%, and 10.7%, while constipation rates were 9.4%,
7.5%, and 8.5% in these two independent studies, and in pooled
data from the two studies, as described in the prescribing infor-
mation, respectively [22–24]). The incidence of dry mouth asso-
ciated with trospium ER compares favorably with the other oral
antimuscarinic drugs used to treat OAB [24,25].
The two Phase III trials of trospium ER 60 mg also included
PROs to determine whether these improvements seen with tro-
spium ER are accompanied by improvements in the QoL of
subjects. This article presents integrated PRO data from the two
Phase III clinical trials of trospium ER 60 mg.
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Subjects and Methods
Pooled data were analyzed from two 12-week, multicenter,
parallel-group, double-blind, placebo-controlled trials conducted
at 117 centers in the United States, the methods of which have
been published previously [22,23].
Men and women aged 18 years with symptoms of OAB for
6 months, symptoms of urgency (i.e., at least one “severe”
urgency severity rating per 3 days, as measured using the vali-
dated Indevus Urgency Severity Scale [26]), minimum urinary
frequency of 30 toilet voids per 3 days, an average of 1 UUI
episode per day, average total volume voided 3000 ml per day,
and 250 ml per void were eligible for inclusion. Exclusion
criteria included: predominant stress, insensate, or overﬂow
incontinence; neurogenic bladder disorder; signiﬁcant renal
disease; urinary tract infection; and signiﬁcant bladder outlet
obstruction. After a 7-day washout period for non-naïve partici-
pants, subjects were randomized (1:1) to receive either trospium
ER 60 mg or matching placebo once daily for 12 weeks. The
randomization schedule was stratiﬁed by the average baseline
daily urinary frequency (collected in bladder diaries) to provide
balance between the treatment groups with respect to this vari-
able. OAB symptom data were collected using 3-day written
bladder diaries at Weeks 1, 4, and 12. The studies were per-
formed according to the principles of the Declaration of Helsinki
and its amendments and the principles of Good Clinical Practice,
with Institutional Review Board approval. All participants pro-
vided written informed consent before taking part in the studies.
The primary end points were the calculated changes in diary-
recorded daily urinary frequency and daily UUI episodes. Sec-
ondary diary-based end points included severity of urgency
associated with toilet voids, volume voided per toilet void, and
urge frequency per day. Safety was assessed by monitoring
adverse events, clinical laboratory values, physical examination,
vital signs, and resting electrocardiograms.
QoL data were obtained at baseline and Week 12 using the
King’s Health Questionnaire (KHQ) and the OAB Questionnaire
(OAB-q). The KHQ is a validated self-administered, OAB
symptom-speciﬁc QoL questionnaire [27]. The instrument con-
tains 21 questions that are scored in nine domains (General
Health Perception, Incontinence Impact, Role Limitations, Physi-
cal Limitations, Social Limitations, Personal Relationships, Emo-
tions, Sleep/Energy, and Severity of Urinary Symptoms). Each
domain is scored from 0 to 100, with higher scores indicating
greater impairment. The threshold of a change from baseline of
5 points on KHQ domains has been suggested to indicate
change that is clinically meaningful to patients [28]. The OAB-q
is a validated 33-item, self-administered symptom bother and
HRQoL questionnaire [29]. This tool is designed to assess the
effect of OAB symptoms (frequency and urgency) in both conti-
nent and incontinent male and female subjects with OAB. The
HRQoL scale consists of 25 items forming four subscales
(coping, concern/worry, social interaction, sleep). Subscale and
total scores were transformed on to a 0 to 100 scale, with higher
scores indicating better HRQoL. An additional eight items form
the Symptom Bother scale. Higher scores on the Symptom Bother
scale indicate increasing symptom bother. A threshold of 10
points has been suggested to represent a minimally important
difference on the OAB-q [30]. Both the KHQ and OAB-q were
scored according to the questionnaire instructions by research
personnel blinded to the patient’s treatment allocation.
Efﬁcacy assessments were performed on the intent-to-treat
subject sample, which included all subjects who were enrolled
(i.e., randomized and dispensed study medication) and had at
least one post–baseline evaluation. Efﬁcacy analyses were per-
formed using the last observation carried forward (LOCF) data
set (to account for missing values), which consisted of data
recorded or carried forward at each visit.
Statistical Analysis
In each individual study, pooled investigator centers that
included at least 40 patients were created from the original
investigational centers. This pooling was performed before the
study blind being broken in either study. These same pooled
centers were used in the integrated analysis, and thus were used
in analyses that required a “center” effect in the models. Change
from baseline in QoL scores (for each domain and overall) were
analyzed using rank analysis of variance models, including effects
for treatment, pooled center, and their interaction; when the
interaction terms were not signiﬁcant (P > 0.10), the interaction
terms were dropped from the efﬁcacy analysis models. P-values
0.05 were considered statistically signiﬁcant.
Results
Overall, 1165 subjects were randomized to receive either tro-
spium ER 60 mg (n = 578) or placebo (n = 587). Baseline char-
acteristics (Table 1) and QoL domain scores (Table 2) were
comparable for the two treatment groups. The study was com-
pleted by 521 placebo recipients (88.8%) and 506 trospium ER
recipients (87.5%; Fig. 1). The primary reasons for premature
discontinuation were adverse events (placebo, 19 subjects
[3.2%]; trospium ER, 30 subjects [5.2%]) and withdrawal of
consent (placebo, 18 [3.1%]; trospium ER, 16 [2.8%]). The
treatment groups were generally similar with regard to the pre-
mature discontinuation rates and reasons.
Among the 2454 subjects considered for enrollment who did
not meet eligibility criteria, the most common reasons were:
urinary frequency average <10/day (approximately 25%); average
total daily volume voided >3000 ml (12%); other medical condi-
tions (e.g., bladder surgeries, irritable bowel disease, renal disease,
interstitial cystitis, neurogenic bladder; 12%); investigator deci-
sion or patient schedule (11%); <7 UUI episodes/week (7%); and
inability to complete diary correctly (3%).
Full details of the individual study results are reported else-
where [22,23]. A statistically signiﬁcantly (P < 0.01) greater
improvement in both primary end points—changes in the
average number of diary-recorded daily toilet voids and daily
UUI episodes—was observed in the trospium ER group at Week
1 when compared with placebo, and was maintained to study
end. The trospium ER group also demonstrated statistically sig-
niﬁcantly greater improvements in urgency severity and volume
voided compared with placebo at Weeks 1, 4, and 12. Treatment-







Female 505 (86.0) 484 (83.7)
Male 82 (14.0) 94 (16.3)
Mean age SE, years 58.9 0.50 60.4 0.54
Race, n (%)
White 493 (84.0) 503 (87.0)
Black 58 (9.9) 44 (7.6)
Hispanic 21 (3.6) 21 (3.6)
Asian 7 (1.2) 5 (0.9)
Other 8 (1.4) 5 (0.9)
ER, extended release; SE, standard error.
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emergent adverse events that were judged by the investigator to
be at least possibly related to study medication and occurring in
1.5% of subjects in either treatment group were dry mouth
(placebo, 3.7%; trospium ER, 10.7%), constipation (placebo,
1.5%; trospium ER, 8.5%), dry eyes (placebo, 0.2%; trospium
ER, 1.6%), ﬂatulence (placebo, 0.5%; trospium ER, 1.6%), and
headache (placebo, 2.4%; trospium ER, 1.4%).
The treatment groups were similar at baseline with respect to
QoL measurements. Following treatment for 12 weeks, patients
treated with trospium ER demonstrated statistically signiﬁcantly
greater improvements (decreased scores from baseline) than
patients treated with placebo for all KHQ domains except
General Health Perceptions and Personal Relationships (Fig. 2).
Trospium ER was also associated with signiﬁcantly greater
improvements in QoL than placebo as assessed using the OAB-q
(Figs. 3 and 4). At Week 12, the improvement from baseline in
mean OAB-q HRQoL total score was signiﬁcantly greater with
trospium ER than with placebo (+25.8 vs. +20.7; P = 0.0003)
(Fig. 3). Trospium ER also produced signiﬁcantly greater
improvements than placebo on the Concern/Worry (P < 0.0001),
Coping (P = 0.0009), and Sleep (P = 0.01) domains of the OAB-q
(Fig. 3). In addition, trospium ER demonstrated signiﬁcantly
greater improvements (decreased scores from baseline) than
placebo in all domains of the OAB-q Symptom Bother scale
(P < 0.05) (Fig. 4). The mean change in total OAB-q Symptom
Bother/Severity score was -31.5 with trospium ER and -23.7
with placebo at Week 12 (P < 0.0001).
Discussion
The present results indicate that the symptomatic improvements
observed in the Phase III trials with trospium ER 60 mg are
accompanied by signiﬁcant improvements in HRQoL when com-
pared with placebo, as assessed using the validated KHQ and
OAB-q measures, over the 12-week study. Patients in the tro-
spium ER group had signiﬁcantly greater improvements from
baseline in scores on the Incontinence Impact, Role Limitations,
Physical Limitations, Social Limitations, Emotions, Sleep/Energy,
and Severity domains of the KHQ, compared with placebo
recipients. Similarly, on the OAB-q HRQoL scale, trospium ER
produced signiﬁcantly greater improvements from baseline than
placebo in the Total Score and scores for the Concern/Worry,
Coping, and Sleep domains. Improvements from baseline on all
eight items of the OAB-q Symptom Bother Scale were signiﬁ-
cantly greater with trospium ER than with placebo, indicating a
beneﬁt with regard to subjects’ own individual assessments of
how troubling their symptoms are to them. These ﬁndings cor-
respond with measures of efﬁcacy; at Week 12, trospium ER
produced signiﬁcantly greater improvements from baseline than
placebo on the coprimary efﬁcacy end points, mean number of
toilet voids/day (-2.7 vs. -1.9; P < 0.001), and mean number of
UUI episodes/day (-2.4 vs. -1.8; P < 0.001), as well as secondary
efﬁcacy end points such as volume voided/toilet void (+30.6 vs.
+18.4 ml; P < 0.001) [31]. The ﬁndings of this pooled analysis of
the QoL data are also similar to the QoL responses observed in
the two individual studies included in this analysis.
The ﬁnding of improvements in sleep is particularly interest-
ing, given the impact that adequate sleep can have on all aspects
of people’s lives. The improvements observed in sleep may reﬂect
the corresponding improvement reported on the OAB-q
Symptom Bother domains “Night time urination” and “Waking
up at night to urinate,” with patients able to experience more
restful sleep because they are less bothered by the need to urinate
during the night.
While objective assessment tools can be useful in measuring a
biologic response to treatment of conditions such as OAB, they
do not reﬂect whether these changes correspond to noticeable
improvements in patients’ daily lives. For this reason,
PROs—encompassing HRQoL (as reported here) as well as
symptom bother (such as assessment of urgency), patient satis-
faction, and patient adherence—have become increasingly
important in clinical trials of treatments for symptom-based con-
ditions such as OAB, as they provide a more comprehensive
method of monitoring treatment beneﬁts than traditional objec-
tive clinical outcomes [32]. The International Continence Society
has recommended that therapeutic interventions aimed at
improving the symptoms of OAB should also be assessed for
their effects on HRQoL [33].
Our data are not only consistent with those for other anti-
muscarinic agents in showing an improvement in disease-speciﬁc
HRQoL (including other large-pooled analyses utilizing the
Table 2 Mean (SE) quality of life domain scores at baseline
Domain Placebo Trospium ER P-value
King’s Health Questionnaire
General health perceptions n = 426 n = 406 0.9084
32.04 (0.58) 31.77 (0.60)
Incontinence impact n = 556 n = 530 0.5115
81.12 (0.92) 80.06 (1.00)
Role limitations n = 539 n = 507 0.6286
63.02 (1.06) 62.23 (1.10)
Physical limitations n = 528 n = 503 0.8227
60.23 (1.11) 59.97 (1.14)
Social limitations n = 521 n = 500 0.7346
42.16 (1.13) 42.13 (1.21)
Personal relationships n = 387 n = 363 0.4250
55.38 (1.53) 57.07 (1.60)
Emotions n = 509 n = 488 0.7585
46.85 (1.19) 47.36 (1.24)
Sleep/energy n = 540 n = 519 0.6524
57.50 (1.11) 56.71 (1.12)
Severity n = 559 n = 535 0.8707
34.07 (0.28) 34.09 (0.31)
Overactive bladder questionnaire
HRQoL scale
Total score n = 559 n = 535 0.6231
51.79 (0.88) 52.11 (0.92)
Concern/worry n = 547 n = 520 0.8528
45.85 (0.99) 45.52 (1.07)
Coping n = 552 n = 526 0.1428
47.23 (1.02) 49.23 (1.05)
Social interaction n = 559 n = 532 0.6234
74.35 (0.99) 74.69 (1.04)
Sleep n = 550 n = 528 0.8868
47.93 (1.08) 47.89 (1.11)
Overactive bladder questionnaire
symptom bother scale
Total symptom bother n = 559 n = 536 0.8463
65.18 (0.71) 65.26 (0.78)
Frequent urination during the
daytime hours
n = 559 n = 536 0.2658
4.57 (0.04) 4.62 (0.04)
An uncomfortable urge to
urinate
n = 559 n = 536 0.6725
4.32 (0.04) 4.32 (0.05)
A sudden urge to urinate with
little or no warning
n = 559 n = 535 0.5986
4.30 (0.05) 4.31 (0.06)
Accidental loss of small
amounts of urine
n = 559 n = 536 0.5388
4.09 (0.05) 4.13 (0.06)
Night time urination n = 558 n = 536 0.1713
4.17 (0.06) 4.07 (0.06)
Waking up at night because
you had to urinate
n = 559 n = 535 0.8091
4.24 (0.06) 4.24 (0.06)
An uncontrollable urge to
urinate
n = 559 n = 536 0.9451
4.25 (0.05) 4.25 (0.05)
Urine loss associated with a
strong desire to urinate
n = 559 n = 536 0.5675
4.13 (0.06) 4.18 (0.06)
ER, extended release; HRQoL, health-related quality of life; SE, standard error.
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KHQ where a similar degree of difference between placebo and
active treatment was observed [34,35]), but are also consistent
with studies using the IR form of trospium chloride. Zinner et al.
showed that 12 weeks of treatment with trospium chloride IR
was associated with a signiﬁcant improvement in the Travel,
Emotional Health, and Social Relationships QoL subscales on
the Incontinence Impact Questionnaire [36]. Fuertes et al. also
showed improved QoL with trospium chloride IR using a generic
HRQoL instrument, the EuroQoL scale [37].
The degree of effect of trospium ER reached the thresholds
suggested to represent a minimally important difference on the
OAB-q [30], and change that is clinically meaningful to patients
on KHQ domains [28]. However, it should be noted that in this
analysis, these thresholds were also reached by patients receiving
placebo; this has also been observed in placebo-controlled studies
of other antimuscarinics in OAB using these instruments
[34,35,38]. The placebo effect on symptoms such as urinary
incontinence and OAB is well known [39]. Reasons are unclear
but may be related to factors such as interactions with health-
care providers during clinical study participation, and increased
awareness of voiding habits and potential risk factors [39]. The
placebo effect is greater with subjective parameters than with
objective measures (such as voided volume) [39]; thus, it is not
surprising that we saw a considerable placebo effect in the QoL
assessments. Given the particular susceptibility of subjective
measures such as QoL to the inﬂuence of the strong placebo
effect observed in OAB studies, it is important to consider QoL
data evaluating treatment effect in the context of more objective
measures of treatment effect. Despite the high level of placebo
response observed in this analysis, the effects of trospium ER
were still signiﬁcantly greater on most items and domains of the
QoL scales, consistent with the signiﬁcant superiority versus
placebo observed on the more objective efﬁcacy parameters,
including volume voided/toilet void.
Figure 1 Disposition of subjects. ER, extended
release.
Figure 2 Mean change from baseline in King’s
Health Questionnaire domain scores at Week 12.
Rank analysis of variance model. A decrease from
baseline indicates improved quality of life. ER,
extended release. *P < 0.05; †P < 0.01; ‡P < 0.001
versus placebo.
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As the only quaternary amine antimuscarinic currently
approved for the treatment of OAB, trospium has a number of
additional properties that make the agent suitable for prescrip-
tion to a wide range of patient groups [40]. These include a low
propensity to cross lipid membranes such as the blood–brain
barrier. This may contribute to a low rate of central nervous
system adverse events, minimizing the potential for negative
effects of such adverse events on QoL. In addition, no clinically
relevant metabolic drug-drug interactions are anticipated with
trospium, based on in vitro data [24]. Trospium is metabolized
by ester hydrolysis and excreted by the kidneys through a com-
bination of tubular secretion and glomerular ﬁltration [24]. In
contrast, the tertiary amines are metabolized hepatically via the
cytochrome P450 system. Two Phase III clinical trials of the new
formulation have demonstrated that trospium ER provides
similar efﬁcacy to that of the IR (20 mg twice daily) formulation,
but with a lower incidence of dry mouth, which should positively
impact QoL [22,23].
Persistence in the use of antimuscarinics as a class is poor
[41,42], and many hypotheses have been put forward to explain
this. It is reasonable to believe that the more tolerable a medica-
tion is, the more likely the patient is to continue using it. Side
effects were the second most common reason for drug discon-
tinuation (after poor efﬁcacy) in a survey of 1447 OAB patients
in the United States [21]. Tolerability must, therefore, be accom-
panied by efﬁcacy to maximize adherence. Patient satisfaction
with treatment was signiﬁcantly associated with compliance in
another survey of 345 OAB patients using ER forms of toltero-
dine or oxybutynin [43]. In this survey, a signiﬁcant determinant
of patient satisfaction with treatment was the impact of OAB
Figure 3 Mean change from baseline in Overac-
tive Bladder Questionnaire–HRQoL Total and
domain subscale scores atWeek 12. Rank analysis
of variance model.An increase from baseline indi-
cates improved quality of life. ER, extended release;
HRQoL, health-related quality of life. *P < 0.05;
†P < 0.001 versus placebo.
Figure 4 Mean change from baseline in Overac-
tive Bladder Questionnaire–Symptom Bother
domain scores at Week 12. Rank analysis of vari-
ance model. A decrease from baseline indicates
improved quality of life. ER, extended release.
*P < 0.05; †P < 0.01; ‡P < 0.001 versus placebo.
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symptoms on their lives (P < 0.001) [43], reinforcing the
importance of evaluating HRQoL in clinical studies of OAB
medications.
It is important to acknowledge the potential limitations of
our study. First, this study was of short duration, and a longer
follow-up is needed to conﬁrm that the results are maintained
during a longer course of treatment. Second, the results were
obtained in a group of OAB patients with speciﬁc minimum
levels of urgency, frequency, and UUI, and may not be general-
izable to patients with characteristics other than those studied.
However, setting these baseline criteria as requirements for
enrollment resulted in a certain severity level among the subjects
that is not always seen in OAB studies. Thus, the study popula-
tion may be representative of patients previously under-
represented in some other studies. In addition, we would expect
the data from subjects with greater symptom severity at baseline
to be generalizable to those with lesser symptom severity. Thirdly,
we used only OAB-speciﬁc HRQoL instruments, and so it is not
possible to compare our ﬁndings with those of studies with
antimuscarinic agents using generic HRQoL instruments or to
compare our baseline data of OAB QoL with those of patients
with other conditions. However, our study included two mea-
sures of HRQoL using widely used and validated disease-speciﬁc
questionnaires, and found results comparable to those with other
antimuscarinics using the same QoL instruments—tolterodine
ER [44], solifenacin [34], and IR or transdermal oxybutynin
[4,45] with the KHQ, and solifenacin and darifenacin with the
OAB-q [38,46].
Although our study was a post hoc pooled analysis, it is not
subject to selection bias, since the data are analyzed for all
patients, using the LOCF method, and not to a subgroup of
selected patients. In fact, the identical nature of the studies and
their robust design (randomized, double-blind, and placebo-
controlled) provide an opportunity to examine outcomes in a
larger patient cohort, and therefore to produce more reliable
results.
This study demonstrates that the symptomatic improvements
resulting from treatment with trospium ER translate into im-
provements in HRQoL, as measured using the KHQ and OAB-q.
HRQoL beneﬁts extended to statistically signiﬁcant improve-
ments in all aspects of subject-perceived symptom bother.
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